Literature DB >> 1656586

Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.

J Zhou1, X Y Sun, D J Stenzel, I H Frazer.   

Abstract

A recombinant vaccinia virus termed pLC201VV was designed to coexpress the L1 and L2 late genes of human papillomavirus type 16 (HPV16). Synthesis of the L1 and L2 proteins occurred in cells infected with pLC201VV, and 40-nm virus-like particles with a density of 1.31 g/ml were produced in the nuclei of cells synthesizing both L1 and L2, but not in cells synthesizing either protein alone. Virus-like particles were partially purified from infected cells by sucrose gradient sedimentation and shown to consist of capsomeres similar to HPV and contain glycosylated L1 viral capsid protein. The production of HPV-like particles using recombinant vaccinia virus should be useful for biochemical studies and could provide a safe source of material for the development of a vaccine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1656586     DOI: 10.1016/0042-6822(91)90772-4

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  110 in total

1.  DNA-induced structural changes in the papillomavirus capsid.

Authors:  C Fligge; F Schäfer; H C Selinka; C Sapp; M Sapp
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection.

Authors:  R B Roden; P M Day; B K Bronzo; W H Yutzy; Y Yang; D R Lowy; J T Schiller
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

3.  Further evidence that papillomavirus capsids exist in two distinct conformations.

Authors:  Hans-Christoph Selinka; Tzenan Giroglou; Thorsten Nowak; Neil D Christensen; Martin Sapp
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

4.  Does human papillomavirus cause pterygium?

Authors:  T W Reid; N Dushku
Journal:  Br J Ophthalmol       Date:  2003-07       Impact factor: 4.638

Review 5.  The development of vaccines: how the past led to the future.

Authors:  Stanley A Plotkin; Susan L Plotkin
Journal:  Nat Rev Microbiol       Date:  2011-10-03       Impact factor: 60.633

6.  The minor capsid protein L2 contributes to two steps in the human papillomavirus type 31 life cycle.

Authors:  Sigrid C Holmgren; Nicole A Patterson; Michelle A Ozbun; Paul F Lambert
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

7.  Maturation of papillomavirus capsids.

Authors:  Christopher B Buck; Cynthia D Thompson; Yuk-Ying S Pang; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

Review 8.  Immunoprevention of human papillomavirus-associated malignancies.

Authors:  Joshua W Wang; Chein-Fu Hung; Warner K Huh; Cornelia L Trimble; Richard B S Roden
Journal:  Cancer Prev Res (Phila)       Date:  2014-12-08

9.  Effects of HPV Pseudotype Virus in Cutting E6 Gene Selectively in SiHa Cells.

Authors:  Yan-Xiang Cheng; Gan-Tao Chen; Xiao Yang; Yan-Qing Wang; Li Hong
Journal:  Curr Med Sci       Date:  2018-04-30

Review 10.  Papillomavirus prophylactic vaccines: established successes, new approaches.

Authors:  M Saveria Campo; Richard B S Roden
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.